Diffuse Large B-Cell Lymphoma (DLBCL)

What is Diffuse Large B-Cell Lymphoma?

DLBCL develops from B-lymphocytes — immune cells responsible for producing antibodies. The disease primarily affects lymph nodes but can also spread to other organs such as the spleen, liver, bone marrow, and central nervous system. Despite its high-grade malignancy, DLBCL is typically very responsive to therapy.

Causes and Risk Factors

While the exact causes of DLBCL remain unclear, several risk factors have been identified:

• Age over 60;
• Immunodeficiency (e.g., HIV infection, post-transplant immunosuppression);
• Autoimmune diseases (such as rheumatoid arthritis);
• Chronic viral infections (e.g., Epstein-Barr virus, hepatitis C);
• Family history or genetic predisposition.

Symptoms of DLBCL

Clinical presentation depends on the tumor location, but common symptoms include:

• Swollen lymph nodes (neck, armpits, groin);
• Unexplained weight loss;
• Persistent fever;
• Night sweats;
• Fatigue and weakness;
• Abdominal or chest pain when internal organs are involved.

These symptoms require immediate medical attention and comprehensive diagnostic evaluation.

DLBCL Diagnostics

DLBCL diagnostics in Russia involves advanced imaging and molecular pathology techniques:

• Lymph node biopsy with histological and immunohistochemical analysis;
• PET-CT scan to determine disease spread;
• Blood tests, including CBC, LDH, and β2-microglobulin;
• Molecular and genetic profiling, including subtype classification (GCB or non-GCB) and key mutations (e.g., MYC, BCL2, BCL6).

These data enable precise diagnosis and individualized treatment planning.

Treatment of DLBCL in Russia

Modern oncology clinics in Russia follow standardized treatment protocols aligned with international guidelines, including:

• Chemotherapy (R-CHOP) — the first-line regimen, which combines rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone;
• High-dose chemotherapy with autologous stem cell transplantation in cases of relapse;
• Targeted and immunotherapies — such as CAR-T cell therapy, BCL2 and BTK inhibitors, particularly for refractory disease;
• Radiation therapy as an adjunct for localized tumors;
• Maintenance therapy and follow-up to support remission and prevent relapse.

Why Choose Treatment in Russia?

Russia offers a high standard of cancer care, including for DLBCL:

• Access to internationally recognized treatment protocols;
• Rapid and comprehensive diagnostic services;
• Personalized therapeutic approaches;
• More affordable costs compared to clinics in Europe and the U.S.

Treating DLBCL in Russia with MARUS

MARUS is a patient-centered platform that facilitates effective and timely treatment for diffuse large B-cell lymphoma at top-tier oncology centers across Russia. We match patients with leading specialists, coordinate diagnostic procedures, online consultations, and manage the entire treatment journey — from initial inquiry to returning home. MARUS provides communication in your native language, full logistical support, and access to advanced therapeutic protocols, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation.  

Rehabilitation and Prognosis

The prognosis for DLBCL depends on the disease stage, patient age, and tumor molecular profile. When treatment is initiated promptly, 60–70% of patients can achieve long-term remission. Post-treatment care includes:

• Regular follow-up evaluations (PET-CT, lab tests);
• Psychological and emotional support;
• Restoration of immune function and gradual return to physical activity.